Amineptine

Summary

Amineptine (CHEMBL418995) is an approved small-molecule dopamine uptake inhibitor (ATC N06AA19); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AA19
• Indications: 1 condition
• Chemistry: 337.5 Da · C22H27NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL418995
Name	Amineptine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	34870
ChEBI	CHEBI:32499
ATC	N06AA19
Molecular formula	C22H27NO2
Molecular weight	337.5
InChIKey	ONNOFKFOZAJDHT-UHFFFAOYSA-N

SMILES: C1CC2=CC=CC=C2C(C3=CC=CC=C31)NCCCCCCC(=O)O

IUPAC name: 7-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylamino)heptanoic acid

ChEBI definition: A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.

Pharmacological roles (ChEBI): dopamine uptake inhibitor, antidepressant.

Also known as: Amineptin, Amineptina, Amineptine, Dea no. 1219, amineptine, AMINEPTINE, SID144206864

Parent form; salt/anhydrous children: CHEMBL1697712

Patent coverage: 1,084 distinct patent families (3,735 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,593 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: 5-hydroxytryptamine receptor 2C, Sodium-dependent dopamine transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2C	6.77	AC50	170	nM	CHEMBL_ACT_25131912
P23977	6	IC50	1000	nM	CHEMBL_ACT_2531671
SLC6A3	5.82	AC50	1500	nM	CHEMBL_ACT_25124055

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).